Dr. Zakaria MD's banner
Dr. Zakaria MD's profile picture

Dr. Zakaria MD

@ZakariaMDv3 • 50,408 subscribers

Exploring alternative & integrative cancer protocols | Patient stories, research shares, hope & support | Not medical advice. Ivermectin. Oncologist. 💪💪🌿🌿❤️

Videos

ZakariaMDv3's profile picture

Ivermectin and Fenbendazole keep coming up in studies. Not the first story I've heard. Probably not the last. But here's what I've learned – from personal experience and from watching others. The Dosage (Simple Rule) If you're taking the paste – no more than the size of your pinky nail per day. Take it for several days, then take a break for a week. Got something chronic? Get advice first. My Experience I was sick in 2023. Took a small dose. The colour came back to my face in one day. Not a miracle. Just a real response. I've also seen viruses improve fast. People I know – really sick – had good results. The Cat, The Cancer, and The Missed Chance I wish I had tried this with my cat, Sam. He had cancer. The vets had no answers. The dose would have been tiny – less than a milligram, based on weight. But I didn't know then what I know now. Why Was It Stopped? It was used routinely. Until Covid. Then suddenly, availability disappeared. You gotta wonder why. Meanwhile, Ivermectin won a Nobel Prize in 2015. And arthritis and cancer share similar inflammatory pathways – Ivermectin has been shown to help both. Be Smart. Be Careful. I'm not a doctor. I recommend talking to NZDSOS – New Zealand Doctors Speaking Out with Science. A body I trust. Find the studies. Keep the dose small. Talk to people who've had good results. One More Thing The problem? They can't make money on a cheap, generic drug. So they don't study it. So they don't promote it.

Dr. Zakaria MD

13,684 просмотров • 2 месяцев назад

ZakariaMDv3's profile picture

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 просмотров • 3 месяцев назад

Больше нет контента для загрузки